Ciprofloxacin-resistant methicillin-resistant Staphylococcus aureus in an acute-care hospital.
about
Penicillin-binding proteins and bacterial resistance to beta-lactamsAntibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756In vitro activity of BAY 12-8039, a new fluoroquinoloneDo we need an intravenous fluoroquinolone?In vitro antibiotic resistance in bacterial keratitis in London.Alternating antibiotic treatments constrain evolutionary paths to multidrug resistanceEfficacy and safety of nadifloxacin for bacterial skin infections: results from clinical and post-marketing studies.In vitro antibacterial activity of Q-35, a new fluoroquinoloneIn vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin.In vitro evaluation of ABT-719, a novel DNA gyrase inhibitor.In vivo therapeutic efficacies of PD 138312 and PD 140248, two novel fluoronaphthyridines with outstanding gram-positive potency.In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone.Canadian ciprofloxacin susceptibility study: comparative study from 15 medical centers. Canadian Ciprofloxacin Study Group.In vitro and in vivo antibacterial efficacies of CFC-222, a new fluoroquinolone.Ciprofloxacin-induced, low-level resistance to structurally unrelated antibiotics in Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureusIn vitro and in vivo evaluations of A-80556, a new fluoroquinoloneComparative prophylactic efficacies of ciprofloxacin, ofloxacin, cefazolin, and vancomycin in experimental model of staphylococcal wound infectionIn vitro antistaphylococcal activities of two investigative fluoroquinolones, CI-960 and WIN 57273, compared with those of ciprofloxacin, mupirocin (pseudomonic acid), and peptide-class antimicrobial agents.In vitro antibacterial activities of PD 138312 and PD 140248, new fluoronaphthyridines with outstanding gram-positive potency.Activity of new quinolones against ciprofloxacin-resistant staphylococciEpidemiologic analysis and genotypic characterization of a nosocomial outbreak of vancomycin-resistant enterococci.Emergence of homogeneously methicillin-resistant Staphylococcus aureusMechanisms of clinical resistance to fluoroquinolones in Staphylococcus aureus.In vitro activity of sparfloxacin and three other fluoroquinolones against methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis.Transcriptomic study of ciprofloxacin resistance in Streptomyces coelicolor A3(2).Spontaneously occurring staphylococcal mutants resistant to clinically achievable concentrations of ciprofloxacin and temafloxacin.Prevalence of antibiotic resistance among clinical isolates of methicillin-resistant staphylococci.Susceptibility of clinical bacterial isolates to ciprofloxacin in the United States.
P2860
Q28257231-E621A97A-E0D7-4564-AB65-003678234651Q28344944-0D550480-D608-4B59-A9F7-B71B0BED0460Q28379381-0C6F4C58-F4CC-4149-A2BC-5418DA9B00C8Q33606570-1D97BD7C-9511-4590-B9BF-1A9D2F85FC38Q33954673-9B011C32-C115-40AF-B864-505F6DD43863Q34407557-1A836B5D-03E8-48BC-899E-769A0289F716Q34438041-C4AA3105-55B0-46CD-8BCE-F585C18594DEQ34537973-456A6621-50A8-4025-AC6B-346658345979Q34601561-375D0B58-2862-48CB-A789-ACD93D0FF977Q35113781-371EAEF3-8EC0-474C-85A8-C148431A685FQ35119128-E9192B76-8929-41D4-8FC4-8F8E41D7E6F3Q35125320-94996687-626E-44AD-A334-963259CBE75BQ35125769-62E759AD-66EC-489A-8ACC-EB3A4DC2F54BQ35138544-3F024D15-CCAD-497D-818F-D085515F2453Q35816058-995D06EC-F7E1-4E33-853A-F87D9AC84EA5Q35820582-5871FD86-3DA4-4AA2-9C34-71EC684DB411Q35821605-B473E874-3C82-4032-BA40-B7D4109C0952Q35846160-5E4FEC7E-C70B-4C26-B4E6-D9CBBA16AF8FQ35904010-FC9ED0EE-A3CC-43FF-B48E-C666A35DA84BQ36754643-E2C72A44-536B-4C28-B1C0-0DBD1B157767Q37068218-31355DB5-18EA-45CF-9ED9-0C3D87475F89Q37247293-B5DA9FC0-9F2F-483D-BA11-5855E235E648Q40088314-2D7731CB-3539-4377-B77C-9BA30CAAF2ABQ41767493-1A701DC0-7E5A-41FD-81A7-A202AC6B631BQ44227947-3F10359A-2C3B-4522-9719-764FB93E2AE1Q44647329-CBF25C76-B6C8-4F7D-8376-EE24AA9FE5CEQ54216097-E14D8E61-7E1E-4C22-AA93-2321624EFC63Q54221191-CAAA1E9C-E00A-4839-979D-EA9272BB2642
P2860
Ciprofloxacin-resistant methicillin-resistant Staphylococcus aureus in an acute-care hospital.
description
1990 nî lūn-bûn
@nan
1990 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1990 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
name
Ciprofloxacin-resistant methic ...... eus in an acute-care hospital.
@ast
Ciprofloxacin-resistant methic ...... eus in an acute-care hospital.
@en
type
label
Ciprofloxacin-resistant methic ...... eus in an acute-care hospital.
@ast
Ciprofloxacin-resistant methic ...... eus in an acute-care hospital.
@en
prefLabel
Ciprofloxacin-resistant methic ...... eus in an acute-care hospital.
@ast
Ciprofloxacin-resistant methic ...... eus in an acute-care hospital.
@en
P2093
P2860
P356
P1476
Ciprofloxacin-resistant methic ...... eus in an acute-care hospital.
@en
P2093
Pablos-Mendez A
Raviglione MC
P2860
P304
P356
10.1128/AAC.34.11.2050
P407
P577
1990-11-01T00:00:00Z